Drug updated on 11/1/2024
| Dosage Form | Tablet (oral; azilsartan/chlorthalidone: 40/12.5 mg and 40/25 mg) |
| Drug Class | Angiotensin II receptor blockers and thiazide-like diuretics |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of hypertension, to lower blood pressure in patients not adequately controlled with monotherapy
- Indicated for the treatment of hypertension, to lower blood pressure as initial therapy in patients likely to need multiple drugs to help achieve blood pressure goals
Latest News
Summary
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- The combination of azilsartan medoxomil (AZL-M) and chlorthalidone (CLD) significantly reduces systolic blood pressure, with studies showing a reduction of -35.1 mm Hg for AZL-M/CLD compared to -29.5 mm Hg for AZL-M with hydrochlorothiazide in clinical settings.
- In a cohort of 153 patients with chronic kidney disease, AZL-M/CLD showed improved adherence compared to other single-pill combination agents, indicating enhanced compliance within this population.
- Among patients with essential hypertension, the combination of AZL-M and CLD demonstrated strong antihypertensive effectiveness, especially in lowering blood pressure and achieving adherence in chronic kidney disease patients.
- The most commonly reported adverse events for azilsartan medoxomil include dizziness, headache, fatigue, upper respiratory tract infection, and urinary tract infection.
- Chlorthalidone, compared to hydrochlorothiazide, is associated with higher serum uric acid levels and lower potassium levels, presenting specific safety concerns.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Edarbyclor (azilsartan medoxomil and chlorthalidone) Prescribing Information. | 2022 | Azurity Pharmaceuticals, Inc., Woburn, MA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Evaluating the Safety and Tolerability of Azilsartan Medoxomil Alone or in Combination With Chlorthalidone in the Management of Hypertension: A Systematic Review | 2021 | Current Hypertension Reviews |
| Single-pill Combination Therapy of Azilsartan Medoxomil/Chlorthalidone for Treatment of Hypertension: A Systematic Review | 2020 | Clinical Therapeutics |